FDA updates medication regimen for chronic lymphocytic leukemia

Share This Post

The US Food and Drug Administration approved Venetoclax (Venclexta) combined with rituximab (VenR) for the treatment of patients with chronic lymphocytic leukemia (CLL) based on the minimal residual disease (MRD) data of the phase III MURANO trial, and the efficacy is significantly better In combination with bendamustine and rituximab (BR) regimen.

The MURANO study found that the efficacy of chemoimmunotherapy for CLL is related to the possibility of achieving MRD conversion, and whether the efficacy of targeted drug treatment for refractory or relapsed CLL is related to MRD conversion, because the rate of MRD conversion in these patients is relatively unknown. low.

The MURANO study showed that VenR regimen had better PFS for refractory or relapsed CLL compared with BR regimen (HR0.17), and the MRD of peripheral blood and bone marrow turned negative. The conversion of MRD to negative in the VenR group was not related to whether the patient had del (17p), non-IGVH mutation, TP53 mutation and other adverse prognostic factors. In the VenR group, 121/194 patients (62%) had MRD negative at the end of the combination therapy. At a median follow-up of 13.8 months (5.6-23.0 months), 100 patients (83%) still had negative MRD and 2 patients Progression to PD, 2 cases died of irrelevant disease, 2 cases progressed to Richter’s syndrome, 15 cases (12%) MRD turned positive [1 case MRD≥10 ^ (-2) and PD, 14 cases MRD 10 ^ (-4) ~ <10 ^ (-2) and 2 of them were PD, 1 died, and 11 still had no progress.

VenR treatment of refractory or relapsed CLL has a high degree of consistency in obtaining peripheral blood and bone marrow MRD conversion, and the status of peripheral blood MRD is significantly related to clinical efficacy. VenR can enable patients to obtain deep and durable high peripheral blood MRD conversion rate at an early stage, and has nothing to do with whether patients have adverse prognostic factors, which is significantly better than the BR program. The recurrence of MRD is only seen in a few patients and may not necessarily lead to clinical disease progression. It is suggested that VenR’s efficacy is significantly better than BR regimen, and it is currently a recommended regimen for refractory or relapsed CLL.



For details on leukemia treatment and second opinion, do call us at +91 96 1588 1588 or write to cancerfax@gmail.com.

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form